Abstract Background: Asthma and COPD are characterized by chronic airway inflammation that results in chronic airway obstruction which is reversible in asthma and non-reversible or partially reversible in COPD. The differential diagnosis between reversible or irreversible airflow obstruction due to asthma or COPD is important in clinical practice because the prognosis and the response to treatment of the two diseases are different. Nitric oxide (NO) is produced by many cells within the respiratory tract. Endogenous NO may play an important signaling role in the physiological control of airway function and in the pathophysiology of airway diseases. Measurement of airway inflammation by means of FENO may be useful and convenient for asthma diagnosis, particularly when bronchial challenges and/or spirometric maneuvers cannot be correctly performed. The increase in the percentage of peripheral blood and sputum eosinophils was found in patients with asthma that correlated with the clinical severity of asthma and pulmonary function. Elevated levels of C-reactive protein (CRP) are established in COPD but, in asthma, the results have been inconsistent. The aim of the present study was to evaluate differences in local (airway) and systemic inflammatory markers among primary care patients with asthma and COPD using simple, rapid and easy to do tests.
the COPD group there was a positive correlation between FENO with all inflammatory markers and PFT with highly significant differences (p 6 .001) with sputum and blood eosinophils and not significantly correlated with hs-CRP and PFT.
Conclusion: It is concluded that there are significant differences in inflammatory patterns between asthma and COPD. FENO and hs-CRP had the highest ability to discriminate between patients with asthma and COPD.
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Background
Asthma and chronic obstructive pulmonary disease (COPD) are increasingly important chronic airway diseases [1] . As well known, asthma is a chronic airway disease characterized by the presence of inflammatory cells and the release of proinflammatory mediators in the airways. Conventional diagnosis of asthma is made by means of the clinical history, measurement of reversible airway obstruction (response to bronchodilators), and an assessment of bronchial hyperresponsiveness by inhalation challenges [2] . Also chronic obstructive pulmonary disease (COPD) is simply considered a lung disease characterized by the presence of fixed and progressive airflow limitation derived from airway inflammation/remodeling associated with the parenchymal destruction the so-called pulmonary emphysema.
However, in most of the COPD patients the disease coexists with several other systemic manifestations which can make health-related quality of life worse and increase mortality [3] . Thus, COPD could no longer be defined as a disease restricted to the lung but might be considered part of a complex chronic systemic disease [4] . Nitric oxide (NO) is produced by many cells within the respiratory tract. Endogenous NO may play an important signaling role in the physiological control of airway function and in the pathophysiology of airway diseases [5] . Endogenous NO is synthesized by the conversion of the amino acid L-arginine to L-citrulline and NO by the enzyme NO synthase (NOS) of which three distinct isoforms exist [6] . Two isoforms, neuronal (nNOS, type I) and endothelial (eNOS, type III), are constitutive and calcium dependant. Both are found in the airway epithelium where they produce picomolar concentrations of NO. The third is inducible (iNOS, type II) and calciumindependent. This is expressed in vivo in the bronchial epithelial cells in both healthy and asthmatic individuals and its activity increases during certain inflammatory processes. It is also expressed in vitro following stimulation by cytokines, endotoxins and lipopolysaccharides and its induction is blocked by glucocorticoids [7, 8] . Inducible NOS produces nanomolar concentrations of NO which remains stable in the gaseous phase and can be assayed [9] .
NOS isoforms also exist in the human pulmonary vasculature, in the bronchial tree and in the parenchyma. NOS is expressed in the following cell types: arterial and venous endothelial cells, epithelial cells, macrophages, mast cells, neutrophils, eosinophils, non-adrenergic non-cholinergic nerves, fibroblasts, smooth muscle cells and platelets. The rise in FENO which is measurable in asthma in particular is attributable to its increased production in bronchial epithelial cells. It plays an important role in the recruiting and activation of eosinophilic granulocytes [10, 11] .
Measurement of airway inflammation by means of FENO may be useful and convenient for asthma diagnosis, particularly when bronchial challenges and/or spirometric maneuvers cannot be correctly performed [12] . Markers of airway inflammation, such as eosinophils from induced sputum and airway biopsy specimens, are elevated in patients with asthma and have been found to correlate with FENO or bronchial hyperreactivity in patients not treated with inhaled corticosteroids [13] .
As a marker of eosinophilic airway inflammation, fractional exhaled nitric oxide (FENO) is increased in patients with asthma [14] . Serum immunoglobulin E (IgE) levels are known to be associated with asthma [15] , and a significant increase in the percentage of peripheral blood eosinophils was found in patients with asthma that correlated with the clinical severity of asthma and pulmonary function. Elevated levels of C-reactive protein (CRP) are established in COPD [16] [17] [18] but, in asthma, the results have been inconsistent. In recent studies high-sensitivity CRP concentrations (hs-CRP) were significantly higher in asthma patients than in controls without obstructive airways disease (OAD) [19, 20] .
FENO levels in COPD are of conflict [21] , but it seems that smoking habits and disease severity are the most important factors influencing exhaled NO levels in these patients [22] . Current smokers [23] and severe COPD patients (particularly in combination with cor pulmonale) [24] show lower levels of exhaled NO than ex-smokers and mild/moderate COPD. Increased exhaled NO levels have been reported in hospitalized patients during an exacerbation of COPD [25] . Interestingly, exhaled NO levels returned to control values only months after discharge of those steroid treated patients, suggesting different inflammatory mechanisms in COPD compared with the highly steroid-sensitive asthmatics [25] .
Aim of the study
The aim of the present study was to evaluate differences in airway and systemic inflammatory markers among primary care patients with asthma and COPD. This might assist the differentiation between asthma and COPD in primary care. Also to evaluate FENO in asthmatic patients and to assess possible correlations between these measurements and the results of tests used in routine diagnosis of asthma (baseline lung function, reversibility of airway obstruction) and other laboratory tests commonly associated with asthma as hs-CRP, percentage of peripheral blood and sputum eosinophils.
Subjects and methods

Study population and design
One hundred and fifty patients and thirty control subjects were included in this study during the period of one year, from May 2013 to April 2014 who attended pulmonary outpatient clinic. They were divided into three groups, ninety asthmatic patients diagnosed clinically and physiologically as reversible airway obstruction (group I). Sixty COPD patients diagnosed by clinical, physiological and laboratory tests to have irreversible or partially reversible airway obstruction (group II). The third group is the control group with no airway obstruction (NAO) including thirty subjects. The exclusion criteria were subjects with respiratory tract infections in the four weeks prior to investigation and subjects with well known contraindications for bronchodilator reversibility testing namely, pregnancy, untreated hyperthyroidism, unstable coronary artery disease, and cardiac arrhythmia.
A written consent was taken from all patients and subjects included in this study after explanation about all the investigations that will be done. All patients and subjects were referred to the lung function unit of the University Hospital for further investigation. Structured medical histories and clinical examination were documented. All subjects underwent full spirometric study, peripheral blood complete blood picture with differential leukocytic count mainly eosinophils, hs-CRP, sputum eosinophil count and exhaled nitric oxide measurement. Patients were instructed not to use any bronchodilator or inhaled steroid and to stop smoking 12 h before visiting the lung function laboratory. The number of pack-years was calculated as years of smoking · number of daily cigarettes. Body mass index (BMI) was calculated as weight (kg)/square of height (m 2 ).
Measurement of FENO, hs-CRP, and differential leukocytic count
Patients underwent measurement of FENO using Niox MinoÒ analyzer (Aerocrine AG, Solna, Sweden) at a mouth flow rate of 50 mL/s over 10 s and a pressure of 10 cmH 2 O according to the guideline recommendation [26] . This procedure was performed at the lung function unit of the University Hospital before doing spirometry as forced inspiratory and expiratory maneuvers can lead to distorted FENO results [27] .
Samples of peripheral venous blood were collected. Serum hs-CRP levels were measured with a high-sensitivity nephelometric assay (ADVIAR 2400 Hematology System, Siemens Healthcare Diagnostics, and Deerfield, IL, USA). Also differential leukocytic count was measured.
Sputum processing
Sputum from all patients was collected. If some patients did not produce sputum, induction of sputum with nebulized hypertonic saline was done. Sputum was treated by adding four volumes of 0.1% dithiothreitol (DTT-Sputolysin 10%; Calbiochem Corp, La Jolla, CA, USA) and mixed by rotating for 30 min at 37°C, followed by four volumes of phosphate buffered saline (PBS). The suspension was filtered through 60 mm nylon gauze (Millipore, North Ryde, NSW, Australia) and a total cell count of leukocytes and viability was determined [28] . A differential cell count was obtained by counting 400 non-squamous cells on slides fixed with methanol and stained with May Grunwald Giemsa. Eosinophils were enumerated as the percentage of 400 cells on slides fixed with methanol and stained with chromotrope 2R. Metachromatic cells were counted as the percentage of 1500 cells on slides fixed in Carnoy's solution and stained with acidic toluidine blue. Cell counts were performed using coded slides by investigators blinded to the clinical characteristics of the subjects [29] .
Pulmonary function tests
Before doing the test, ambient temperature and pressure were entered with the patient data (age in years, weight in kilograms, height in centimeters and sex) so that all results were calculated as percent of predicted (% predicted
An obstructive airway disease (OAD) was diagnosed if FEV1/forced vital capacity (FVC) was 60.7. The obstruction was classified as fully reversible (indicating 'asthma') if the postbronchodilator FEV1 was improved >12% and >200 mL from baseline and lung volumes returned to the predicted normal range. The obstruction was classified as irreversible (indicating COPD) if the degree of reversibility in FEV1 was less than 12% compared with baseline and was below 200 mL. In case FEV1/FVC was >0.7 and still patient complains of chest tightness, FEF25-75% will be taken as a measure for airway obstruction if it was 60.7. It indicates small airway obstruction.
Statistical analysis
Quantitative data were presented as means and standard deviation (SD) values. Student's t-test was used for comparisons between means of two groups. Pearson's correlation coefficient was used to determine significant correlations between the different variables. The significance level was set at p 6 0.05. Statistical analysis was performed with SPSS version 19.0 (statistical package for scientific studies) for windows. Boxplots were constructed to illustrate the dispersion of each inflammatory marker by diagnosis.
Results
Patients' demographic data show that the means of ages and BMI for all groups are matched. There were 129 males and 51 females of who 66 were currently smoked, 37 ex-smokers and 77 never smoked ( Table 1) . As regards pulmonary function tests, the mean value of FEV1/FVC was less than 70% in asthmatic and COPD patients but above ninety in control subjects with NAO. Also the means of FVC, FEV1 and FEF25-75% were lesser in asthmatic and COPD patients than control subjects (Table 2) . COPD patients had significantly higher levels of hs-CRP than asthma patients (p = 0.016) and subjects with no OAD. All other inflammatory markers showed highly significant differences between asthma and COPD with much higher levels in asthma (p 6 .001) ( Table 3 and Fig. 1) .
FENO was positively correlated with all inflammatory markers in the asthmatic group with highly significant differences (p 6 .001) and negatively correlated with age, BMI and PFTs. In the COPD group there was a positive correlation between FENO with all inflammatory markers and PFT with highly significant differences (p 6 .001) with sputum and blood eosinophils and not significantly correlated with hs-CRP and PFT. In the control group with NAO, the FENO was positively correlated with sputum eosinophil % and negatively correlated with other inflammatory markers with highly significant difference in all variables (Table 4 and Fig. 2) .
The results showed that percentage of sputum eosinophils in asthmatic patient has the highest sensitivity (89%) but least specificity (50%). FENO has the highest accuracy (sensitivity 79% and specificity 71%). Hs-CRP has the highest sensitivity and specificity in COPD (92% and 59% respectively). FENO, sputum and blood eosinophils have no role in the diagnosis of COPD where sensitivity and specificity cannot be calculated (Table 5) .
Discussion
According to the Foundation for the National Institutes of Health Biomarkers Consortium, biomarkers are defined as ''characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention'' [30] . The most useful biomarkers are those with the most direct relationship between the marker and the central pathobiological characteristics of a disease process. Figure 1 Box plots illustrating the distribution of (a) fractional exhaled nitric oxide (FENO), (b) high-sensitivity C-reactive protein (hs-CRP), (c) blood eosinophil % and (d) sputum eosinophil % within the diagnostic groups.
Eosinophil count in induced sputum and FENO can both serve as direct biomarkers for asthma inflammation in the lungs. These biomarkers are advantageous in that they tend to remain elevated even when patients are asymptomatic, and decrease in the presence with ICS. Sputum induction is safe and reproducible, though it is a semi-invasive procedure which cannot be successfully accomplished in up to 13% of adult patients with asthma, and even in a greater percentage of children [31] . The technique of measuring FENO, in contrast, is non-invasive and well-tolerated. FENO measurements are instantaneous, thus, facilitating decision-making at the point of care.
Asthma and COPD are characterized by chronic airway inflammation that results in chronic airway obstruction which is reversible in asthma and non-reversible or partially reversible in COPD. The differential diagnosis between reversible or irreversible airflow obstruction due to asthma or COPD is important in clinical practice because the prognosis and the response to treatment of the two diseases are different [32] . The current study had evaluated the use of FENO measurement to differentiate between both diseases in comparison with other inflammatory markers. Variables such as sex, current asthma, allergic rhinitis, smoking, current use of inhaled corticosteroids, atopy and seasonality have all been previously identified as important explanatory factors that influence FENO levels [33] [34] [35] [36] .
The most important finding of the present study is that there were distinctive inflammatory profiles in patients with asthma compared with COPD patients, thereby identifying different aspects of inflammation in OAD. The results of this study showed that asthma has higher levels of FENO, sputum and blood eosinophil percentage which were in agreement with 
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CorrelaƟon coefficient (r) for COPD Figure 2 Correlation coefficient (r) for asthma and COPD groups: the levels above the horizontal axis represent positive correlation while levels below it represent negative correlation. previous studies [1, 12, 13, 30] compared with low levels in COPD patients. The overall, hs-CRP had the highest diagnostic accuracy in COPD with higher levels in COPD than in asthma matched with other previous studies [32, 37] . The results of the study showed that exhaled nitric oxide is a weak predictor in patients with COPD and that a normal or low test result could help clinicians decide to avoid prescriptions of oral corticosteroid treatment that may be unnecessary. This result was in agreement with other previous study [38] . These observations help us to expect that those patients with COPD would have greater systemic inflammatory marker activation and those with asthma would have more local inflammatory marker activation. Consistent with other research, the sensitivities and specificities of FENO showed that it is a good test for ruling asthma out but not so good at ruling it in. This is due to the increase in FENO in bronchial hyperreactivity and other eosinophilic inflammatory disorders specially if not associated with airway obstruction. Similar but less discriminatory findings were reported for blood eosinophilia. Hs-CRP had reasonable sensitivity but a specificity of only 50% for COPD, so had a high false positive rate ( Table 5) .
As regards smoking, the number of pack-years was positively correlated with hs-CRP levels. Thus, smoking history may influence the levels of inflammatory markers. The correlation was even stronger when the analysis was restricted to subjects with OAD.
Age was found to be negatively correlated with FENO in the present study. Possible mechanisms included airway surface area-related changes in NO diffusion coefficients and age-dependent recurrent immunologic stimulation leading to the induction of NOS [39] [40] [41] . As regards effect of sex on the results, there was an independent negative association of female sex with FENO, consistent with previous studies [42] [43] [44] [45] [46] [47] [48] . The sex effect could be due to differences in airway surface area, diameter, and NO dilution [49] variants in the neuronal NOS 1 gene [50] and the suppressive effects of estrogen on NO synthase expression [43] .
It has been demonstrated that standardized FENO measurements performed with NIOXÒ system are simple, free from diurnal and day-to-day variation and acceptable by patients. Exhaled nitric oxide measurement provides immediate non-invasive measurement of the airway inflammatory status. This quick, easy and non-invasive tool can help in a good control and management of asthma. The ENO value improves diagnostic accuracy [51, 52] , predicts steroid response [53] and determines the best treatment for chronic cough [54] . Both low and high values are of clinical significance [55] . It improves the patient's understanding and improves the compliance [56, 57] . It is cost effective [58] , optimizes dose-adjustments [59, 60] . It predicts asthma relapse [61] .
Conclusion
The results of the current study conclude that there are significant differences in inflammatory patterns between asthma and COPD. In COPD patients there is an increase in hs-CRP concentrations whereas blood eosinophils, FENO, and sputum eosinophils were increased in patients with asthma. FENO and hs-CRP had the highest ability to discriminate between patients with asthma and COPD. Exhaled nitric oxide measurement provides, simple, immediate and non-invasive measurement of the airway inflammatory status.
